The groundbreaking partnership between exteRNA and Moderna is set to accelerate drug discovery in Australia, particularly in the field of mRNA medicines. This collaboration, formalized in 2023, aims to transform innovative research into viable preclinical drug candidates, leveraging the strengths of both entities to combat diseases more effectively.
Vi, a researcher with a profound passion for biology, leads the efforts at exteRNA. His journey into science was deeply personal, driven by the loss of his mother to breast cancer when he was just 18. This tragedy fueled his determination to find new ways to treat diseases, steering him towards RNA research. Over the years, his lab has made significant strides in RNA biology, culminating in the creation of exteRNA.
The Birth of a Pioneering Partnership
In 2023, Vi’s lab was recognized for its world-leading research with the inaugural Moderna Australia Fellowship. This accolade not only acknowledged the lab’s contributions but also paved the way for a deeper collaboration with Moderna. The partnership evolved into the MATE platform, a pioneering program that provides WEHI researchers access to Moderna’s cutting-edge technology for developing mRNA medicines.
Vi recalls his first interaction with Kate, a key figure at Moderna, during a 7am Zoom call in 2022. Despite Moderna’s inability to invest directly in exteRNA, Kate’s belief in the potential of their science marked a turning point. Her support has been instrumental in elevating the profile of RNA research in Australia, creating a hub for mRNA research and innovation.
Moderna’s Vision and Global Impact
Kate’s journey into science was less conventional, with her initial interests lying in netball and music. However, her academic pursuits at Melbourne University and the Garvan Institute ignited a passion for immunology, a field that bridges fundamental biology and human health. Her career trajectory led her to Moderna, where she now leads drug discovery efforts.
Moderna’s approach to mRNA technology is expansive, aiming to redefine medicine beyond vaccines. The company is exploring treatments for autoimmune and inflammatory diseases, rare conditions, and various cancers. Notably, Moderna is investigating solutions for VEXAS syndrome, a recently discovered autoinflammatory disease with a high mortality rate.
“Moderna has been at this for 15 years – it is one of few companies to make mRNA-based medicines safely, at scale and ready for clinical use.”
Shared Vision for Global Health Advancements
The collaboration between exteRNA and Moderna exemplifies the power of shared vision and resources in scientific advancement. By connecting the right people with the right tools, the partnership aims to push the boundaries of what mRNA technology can achieve, ultimately improving health outcomes worldwide.
Vi and Kate’s partnership is a testament to the belief that science knows no borders. Their combined efforts are not just about sharing technology but also about fostering trust, expertise, and a shared commitment to innovation. As the partnership continues to evolve, it promises to deliver groundbreaking solutions to some of the most pressing medical challenges of our time.
Looking ahead, the collaboration is poised to make significant contributions to the global landscape of mRNA research, setting a precedent for future partnerships in the field. With the support of Moderna’s resources and expertise, exteRNA is well-positioned to lead the charge in mRNA drug discovery, offering hope for new treatments and therapies.
